Silo Pharma Inc. (NASDAQ: SILO), a developmental-stage biopharmaceutical company specializing in novel therapeutics and drug delivery systems, announced that its representatives will attend the IPAC-RS 2026 Nasal Innovation Forum, scheduled for September 16-17, 2026, in Jersey City, New Jersey. This participation highlights the company's ongoing efforts to advance SPC-15, its innovative nose-to-brain drug delivery system designed for the treatment of post-traumatic stress disorder (PTSD).
CEO Eric Weisblum emphasized the importance of the forum, stating that it provides a valuable opportunity to engage with experts in nasal drug development as Silo continues to refine its approach. The company's focus on targeted drug delivery through the nasal route is part of a broader strategy to address underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases.
Preclinical data presented by Silo demonstrate the potential of SPC-15. The formulation and device met predefined specifications for assay, impurities, pH, and microbiological quality over a nine-month period. Additionally, six-month accelerated stability data were consistent and aligned with long-term findings, suggesting that the product maintains its integrity and efficacy under various storage conditions. These results are critical for regulatory approval and eventual commercialization.
The significance of this announcement lies in the growing interest in alternative drug delivery methods. Nasal delivery offers a non-invasive route that can bypass the blood-brain barrier, potentially providing faster onset of action and improved bioavailability for central nervous system disorders. For PTSD, which affects millions worldwide, current treatments often involve oral medications with systemic side effects and delayed efficacy. A nose-to-brain approach could offer a more targeted and rapid therapeutic effect, addressing an unmet medical need.
Silo Pharma's participation in the IPAC-RS forum is not just a networking opportunity but a chance to showcase its scientific advancements to key opinion leaders and potential partners. The company's pipeline includes SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. These programs are developed in collaboration with leading universities and laboratories, enhancing their credibility and scientific foundation.
For investors and industry observers, this news reinforces Silo's commitment to innovation in drug delivery. The stability data for SPC-15 is encouraging, as it reduces formulation risks and supports the feasibility of the product. However, it is important to note that preclinical success does not guarantee clinical efficacy. The company will need to conduct rigorous clinical trials to demonstrate safety and effectiveness in humans.
The forum, organized by IPAC-RS, an international consortium focused on regulatory science for inhaled and nasal products, provides a platform for discussing emerging trends, regulatory challenges, and technological breakthroughs. Silo's involvement indicates its proactive approach to staying at the forefront of nasal drug development.
As the event approaches, stakeholders will be watching for any additional data or announcements from Silo regarding its clinical timelines and partnerships. The company's ability to translate its preclinical findings into successful clinical outcomes will be crucial for its long-term success and for providing new treatment options for patients suffering from PTSD and other CNS conditions.
For more information about Silo Pharma and its pipeline, visit the company's website at silopharma.com. The full press release regarding this announcement is available at https://ibn.fm/Dy4qf.
